APA Annual Meeting 2026

NeuroKaire participated in the 2026 APA Annual Meeting, held May 16–20 in San Francisco—one of the world's premier gatherings for psychiatrists, researchers, and mental health professionals. The meeting featured more than 400 educational sessions, cutting-edge scientific presentations, and opportunities to explore the future of mental healthcare.

Throughout the conference, our team connected with clinicians, researchers, and healthcare innovators to discuss how NeuroKaire is bringing precision medicine to psychiatry. Through a simple blood test, NeuroKaire leverages patient-derived neurons and advanced AI to help predict antidepressant response, supporting more personalized and data-driven treatment decisions for patients living with depression.

APA 2026 provided an important opportunity to engage with leaders across psychiatry and share the latest advances in patient-specific neuroscience, biomarker-driven care, and the growing field of precision psychiatry.

Highlights:

• Connecting with psychiatrists, researchers, and healthcare leaders from around the world
• Showcasing BrightKaire™ and NeuroKaire's patient-derived neuron platform
• Discussing AI-driven approaches to antidepressant treatment selection
• Exploring the future of precision psychiatry and personalized mental healthcare
• Sharing how biologically informed insights can help reduce trial-and-error prescribing

We are grateful to everyone who visited us during the meeting and contributed to the conversation around the future of mental health treatment. As precision medicine continues to transform healthcare, NeuroKaire remains committed to developing innovative solutions that help clinicians make more informed treatment decisions and improve patient outcomes.

Missed Us at APA?

If you weren’t able to attend, we’d still love to connect! Learn more about how NeuroKaire’s solutions can benefit your practice and improve patient outcomes.

Contact Us or Schedule a Meeting